200 related articles for article (PubMed ID: 19805356)
1. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.
Moore LM; Holmes KM; Smith SM; Wu Y; Tchougounova E; Uhrbom L; Sawaya R; Bruner JM; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16675-9. PubMed ID: 19805356
[TBL] [Abstract][Full Text] [Related]
2. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma.
Tchougounova E; Kastemar M; Bråsäter D; Holland EC; Westermark B; Uhrbom L
Oncogene; 2007 Sep; 26(43):6289-96. PubMed ID: 17438529
[TBL] [Abstract][Full Text] [Related]
3. Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.
Robinson JP; VanBrocklin MW; Guilbeault AR; Signorelli DL; Brandner S; Holmen SL
Oncogene; 2010 Jan; 29(3):335-44. PubMed ID: 19855433
[TBL] [Abstract][Full Text] [Related]
4. Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.
Vanbrocklin MW; Robinson JP; Lastwika KJ; McKinney AJ; Gach HM; Holmen SL
Neuro Oncol; 2012 Jan; 14(1):34-42. PubMed ID: 22015595
[TBL] [Abstract][Full Text] [Related]
5. SCCRO promotes glioma formation and malignant progression in mice.
Broderick SR; Golas BJ; Pham D; Towe CW; Talbot SG; Kaufman A; Bains S; Huryn LA; Yonekawa Y; Carlson D; Hambardzumyan D; Ramanathan Y; Singh B
Neoplasia; 2010 Jun; 12(6):476-84. PubMed ID: 20563250
[TBL] [Abstract][Full Text] [Related]
6. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
Robinson JP; Vanbrocklin MW; Lastwika KJ; McKinney AJ; Brandner S; Holmen SL
Oncogene; 2011 Mar; 30(11):1341-50. PubMed ID: 21057530
[TBL] [Abstract][Full Text] [Related]
7. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.
Labuhn M; Jones G; Speel EJ; Maier D; Zweifel C; Gratzl O; Van Meir EG; Hegi ME; Merlo A
Oncogene; 2001 Mar; 20(9):1103-9. PubMed ID: 11314047
[TBL] [Abstract][Full Text] [Related]
8. Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.
Phillips LM; Zhou X; Cogdell DE; Chua CY; Huisinga A; R Hess K; Fuller GN; Zhang W
J Pathol; 2016 Jul; 239(3):355-64. PubMed ID: 27125842
[TBL] [Abstract][Full Text] [Related]
9. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
[TBL] [Abstract][Full Text] [Related]
10. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.
Kim HS; Woolard K; Lai C; Bauer PO; Maric D; Song H; Li A; Kotliarova S; Zhang W; Fine HA
Cancer Res; 2012 Nov; 72(22):6065-75. PubMed ID: 22986743
[TBL] [Abstract][Full Text] [Related]
11. Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence.
Tchougounova E; Jiang Y; Bråsäter D; Lindberg N; Kastemar M; Asplund A; Westermark B; Uhrbom L
Oncogene; 2009 Mar; 28(12):1537-48. PubMed ID: 19219070
[TBL] [Abstract][Full Text] [Related]
12. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping.
Higgins RJ; Dickinson PJ; LeCouteur RA; Bollen AW; Wang H; Wang H; Corely LJ; Moore LM; Zang W; Fuller GN
J Neurooncol; 2010 May; 98(1):49-55. PubMed ID: 19967449
[TBL] [Abstract][Full Text] [Related]
14. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis.
Ferletta M; Uhrbom L; Olofsson T; Pontén F; Westermark B
Mol Cancer Res; 2007 Sep; 5(9):891-7. PubMed ID: 17855658
[TBL] [Abstract][Full Text] [Related]
15. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis.
Ji P; Zhou X; Liu Q; Fuller GN; Phillips LM; Zhang W
Oncotarget; 2016 Apr; 7(17):23521-9. PubMed ID: 26993778
[TBL] [Abstract][Full Text] [Related]
16. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.
Bruggeman SW; Hulsman D; Tanger E; Buckle T; Blom M; Zevenhoven J; van Tellingen O; van Lohuizen M
Cancer Cell; 2007 Oct; 12(4):328-41. PubMed ID: 17936558
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor binding protein 2 promotes glioma development and progression.
Dunlap SM; Celestino J; Wang H; Jiang R; Holland EC; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11736-41. PubMed ID: 17606927
[TBL] [Abstract][Full Text] [Related]
18. Specific Deletion of p16
Ishida K; Tomita H; Kanayama T; Noguchi K; Niwa A; Kawaguchi M; Miyai M; Matsuo M; Imaizumi Y; Kato K; Hatano Y; Hirata A; Okada H; Shibata T; Hara A
Am J Pathol; 2020 Jun; 190(6):1332-1342. PubMed ID: 32194051
[TBL] [Abstract][Full Text] [Related]
19. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model.
Doucette T; Rao G; Yang Y; Gumin J; Shinojima N; Bekele BN; Qiao W; Zhang W; Lang FF
Neoplasia; 2011 Aug; 13(8):716-25. PubMed ID: 21847363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
